Imagine a detective trying to solve a complex case. They search for clues, gather evidence, and piece together the puzzle to find the truth. In a similar way, scientists are on the hunt for biomarkers – unique signs in our bodies that can reveal important information about diseases. Chronic traumatic encephalopathy (CTE) is one such disease, typically found in individuals with a history of repetitive brain injuries. However, diagnosing CTE has been a challenge. To address this, researchers are investigating the multi-omics landscape of an observational cohort, searching for potential blood biomarkers that could help identify CTE earlier and more accurately. By analyzing blood samples and exosomes – tiny packages released by cells – researchers have discovered certain proteins and molecules that show different levels of expression between healthy individuals and those with CTE. These findings open up exciting possibilities for developing a new set of diagnostic signatures for CTE, which could be integrated into the existing diagnostic criteria framework. So, just like a detective moves closer to solving a case with every clue they discover, scientists are making progress towards better understanding and diagnosing CTE. To dive deeper into the research and explore how these blood biomarkers could revolutionize CTE diagnosis, check out the full article!

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with exposure to repetitive head impacts, which is susceptible in elderly people with declined mobility, athletes of full contact sports, military personnel and victims of domestic violence. It has been pathologically diagnosed in brain donors with a history of repetitive mild traumatic brain injury (rmTBI), but cannot be clinically diagnosed for a long time. By the continuous efforts by neuropathologists, neurologists and neuroscientists in recent 10 years, an expert consensus for the diagnostic framework of CTE was proposed in 2021 funded by the National Institute of Neurological Disorders and Stroke. The new consensus contributes to facilitating research in the field. However, it still needs to incorporate in vivo biomarkers to further refine and validate the clinical diagnostic criteria. From this, a single-center, observational cohort study has been being conducted by Tianjin Medical University General Hospital since 2021. As a pilot study of this clinical trial, the present research recruited 12 pairs of gender- and age-matched rmTBI patients with healthy subjects. Their blood samples were collected for exosome isolation, and multi-omics screening to explore potential diagnostic biomarkers in blood and its exosomes. The expression level of CHL1 protein, KIF2A mRNA, LIN7C mRNA, miR-297, and miR-1183 in serum and exosomes were found to be differentially expressed between groups. Besides, serum and exosomal CHL1, KIF2A, and miR-1183, as well as exosomal miR-297 were further verified as potential biomarkers for CTE by low-throughput assays. They are expected to contribute to establishing a novel set of CTE diagnostic signatures with classic neurodegenerative indicators in our future study, thereby updating the consensus diagnostic criteria for CTE by incorporating new evidence of the in vivo biomarkers.

Read Full Article (External Site)